Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.

摘要

Many personalized medicine tests have been found to be relatively cost-effective, although fewer have been found to be cost saving, and many available or emerging medicine tests have not been evaluated. More evidence on value will be needed to inform decision making and assessment of genomic priorities.